Dana-Farber Cancer Institute Inc. has divulged proteolysis targeting chimeras (PROTACs) comprising a cereblon (CRBN) binding moiety covalently linked to a histone-lysine N-methyltransferase, H3 lysine-79 specific (DOT1L) targeting moiety via linker reported to be useful for the treatment of cancer.
Gluetacs Therapeutics (Shanghai) Co. Ltd. has synthesized compounds targeting protein cereblon (CRBN) and their PROTACs (proteolysis targeting chimeras) reported to be useful for the treatment of cancer, anemia, transplant rejection, neurodegeneration, infections, autoimmune, inflammatory and metabolic disorders, among others.
Researchers from Sun Yat-Sen Memorial Hospital and affiliated organizations published data from a study that aimed to explore the mechanism of prostate cancer (PCa) metastasis to discover an intrinsic biomarker for metastatic PCa (mPCa).
Lhotse Bio Inc. has identified lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists reported to be useful for the treatment of cancer and fibrosis, among others.
Researchers at Voronoi Bio Inc. and Voronoi Inc. have disclosed receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of cancer, inflammatory bowel disease, psoriasis, rheumatoid arthritis, myocardial infarction, Alzheimer's disease, asthma and type 1 diabetes, among others.
Bayer AG’s diacylglycerol kinase ζ (DGK-ζ) inhibitor BAY-2965501 is being developed as a first-in-class cancer immunotherapy candidate. The company recently presented preclinical data on the compound, which supported advancement of the candidate into clinical testing, with a first-in-human phase I study in solid tumors underway (NCT05614102).
Osteosarcoma (OS) is an aggressive cancer type, with frequent metastasis seen in the lungs, and for which two-thirds of metastatic patients fail to achieve durable responses and die due to the disease.
RSS
